NICE Recommends Against Fludarabine For First-Line Treatment Of CLL
This article was originally published in The Pink Sheet Daily
Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.
You may also be interested in...
Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.
Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.